Navigation Links
An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients
Date:4/24/2009

The results of the largest study performed to date will be presented during the International Society for Heart and Lung Transplantation Annual Meeting in Paris, France on April 24, 2009

COLUMBIA, Md., April 24 /PRNewswire/ -- Since it was cleared as an in vitro assessment of cell-mediated immunity in immunosuppressed patient populations, numerous clinical investigations have contributed to defining the role of the Cylex ImmuKnow assay among recipients of solid organ transplants.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090424/NE99362 )

In the largest immune monitoring experience in heart transplantation, investigators at UCLA's David Geffen School of Medicine followed 337 cardiac transplant patients with ImmuKnow to determine whether ImmuKnow assay values can be correlated with the incidence of infection or rejection.

The lead investigator, Jon Kobashigawa, MD, favorably remarked, "These results suggest that ImmuKnow as a non-invasive immune monitoring is indeed a promising means for individualizing immunosuppression in heart transplant recipients."

"This study expands our understanding of the applicability of the ImmuKnow immune function assay in effective management of heart transplant recipients in the post-transplant setting," stated Dr. Kobashigawa. Additionally, Kobashigawa and his colleagues conclude that the noninvasive ImmuKnow assay appears to predict infection with the promise of balancing risk of infection and rejection in heart transplant patients pending additional larger studies.

As described in this study, the use of the ImmuKnow assay for identifying patients at risk for infection or rejection following heart transplantation has not been cleared by the U.S. Food & Drug Administration. The Company may use data from this or similar studies to support future FDA marketing applications.

About ImmuKnow

ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. The use of the ImmuKnow assay as described in this study has not been cleared by the FDA. The company may use data from this or similar studies to support a future FDA marketing application for a similar indication.

About Cylex, Inc.

Cylex is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides an innovative platform allowing clinicians to simply and reproducibly assess CMI. The Company is based in Columbia, MD USA.


'/>"/>
SOURCE Cylex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
2. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
3. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
4. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
5. Mindset Media Study Reveals Which Independent Voters Favor Obama Vs. McCain
6. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
7. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
8. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
9. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
10. Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
11. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 --> ... Inflammation Global Clinical Trials Review, H2, 2015 provides ... clinical trials landscape along with top level data ... (G7 & E7), Trial Status, Trial Phase, Sponsor ... companies involved and enlists all trials (Trial title, ...
(Date:2/11/2016)... The primary goal of this research is to analyze ... of liquid biopsy. Key information the survey seeks to ... liquid biopsy adoption amidst future users - Predominantly used ... Sample inflow to conduct liquid biopsy tests - Preference ... on. - Correlation analysis of sample type and biomarker ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... The Company also filed its Quarterly Report on Form 10-Q ... Securities and Exchange Commission today. --> ... --> --> Net sales for the ... 95%, to $5.4 million from $2.8 million for the three ...
Breaking Medicine Technology:
(Date:2/12/2016)... Highlands Ranch, Colo. (PRWEB) , ... February 12, 2016 , ... ... particularly over the past 35 years. A president has access to health and wellness ... leader of the free world, no single individual has a schedule as frenetic as ...
(Date:2/12/2016)... ... ... The Central Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter ... teens with and without special needs to gather in a safe and supportive environment. Volunteers ... will take place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, ...
(Date:2/12/2016)... ... 12, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... he says are the real facts surrounding all those Bible stories. For generations families ... school teachers, and Yisrayl says there is more to these than just mere “stories”. ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Planet ... Studios. The new cartoon style themes are great for showcasing pictures, videos as well ... scene generators, titles like introductions, lower thirds, transitions and a beautiful frame overlay. Pixel ...
(Date:2/12/2016)... ... February 12, 2016 , ... Dignity Health named Dr. Scott Bingham the ... The new facility is licensed under Dignity Health Arizona General Hospital , ... excellent leader and will ensure our new freestanding emergency room delivers the highest quality ...
Breaking Medicine News(10 mins):